Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L03AB11 PEGINTERFERON alfa-2a SOL. INJ. 135 µg/ml

PEGASYS 135 µg/ml 135 µg/ml ROCHE REGISTRATION LTD.
L03AB11 PEGINTERFERON alfa-2a SOL. INJ. ÎN SERINGĂ 180 µg/0.5 ml

PREUMPLUTĂ

PEGASYS 180 µ/0,5 ml 180 µ/0.5 ml ROCHE REGISTRATION LTD.

________________________________________________________________________________

______________________________________________________________________________

| 401 |N04BB01| AMANTADINUM** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

N04BB01 AMANTADINUM CAPS. 100 mg

VIREGYT(R)-K 100 mg EGIS PHARMACEUTICALS LTD.

________________________________________________________________________________

SUBLISTA C1 - G5 HEPATITA AUTOIMUNĂ.
______________________________________________________________________________

| 402 |H02AB04| METHYLPREDNISOLONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ. 125 mg

LEMOD SOLU 125 mg 125 mg HEMOFARM S.R.L
H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. 125 mg/2 ml

SOL. INJ.

SOLU - MEDROL ACT-O-VIAL 125 mg/2 ml PFIZER EUROPE MA EEIG
H02AB04 METHYLPREDNISOLONUM COMPR. 16 mg

MEDROL A 16 16 mg PFIZER EUROPE MA EEIG

H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ. 20 mg

LEMOD SOLU 20 mg 20 mg HEMOFARM S.R.L.

H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. 250 mg/4 ml

SOL. INJ.

SOLU - MEDROL ACT-O-VIAL 250 mg/4 ml PFIZER EUROPE MA EEIG
H02AB04 METHYLPREDNISOLONUM COMPR. 32 mg

MEDROL 32 32 mg PFIZER EUROPE MA EEIG

H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ. 40 mg

LEMOD SOLU 40 mg 40 mg HEMOFARM S.R.L.

H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. 40 mg/1 ml

SOL. INJ.

SOLU - MEDROL ACT-O-VIAL 40 mg/1 ml PFIZER EUROPE MA EEIG
H02AB04 METHYLPREDNISOLONUM COMPR. 4 mg

MEDROL 4 mg 4 mg PFIZER EUROPE MA EEIG

H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ. 500 mg

LEMOD SOLU 500 mg 500 mg HEMOFARM S.R.L.

H02AB04 METHYLPREDNISOLONUM LIOF. + SOLV. PT. SOL. 500 mg/7.8 ml

INJ.

SOLU - MEDROL 500 mg/7,8 ml 500 mg/7.8 ml PFIZER EUROPE MA EEIG

________________________________________________________________________________

______________________________________________________________________________

| 403 |H02AB06| PREDNISOLONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB06 PREDNISOLONUM LIOF. + SOLV. PT. SOL. 250 mg

INJ.

SOLU - DECORTIN H 250 250 mg MERCK KGAA

H02AB06 PREDNISOLONUM LIOF. + SOLV. PT. SOL. 50 mg

INJ.

SOLU - DECORTIN H 50 50 mg MERCK KGAA

________________________________________________________________________________

______________________________________________________________________________

| 404 |L04AX01| AZATHIOPRINUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
SUBLISTA C1 - G06 CIROZA BILIARĂ PRIMARĂ, COLANGITA SCLEROZANTĂ PRIMITIVĂ, HEPATITA CRONICĂ ŞI CIROZE DE ALTE ETIOLOGII CU COLESTAZĂ.
______________________________________________________________________________

| 405 |A05AA02| ACIDUM URSODEOXYCHOLICUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A05AA02 ACIDUM CAPS. 300 mg

URSODEOXYCHOLICUM

URSOFALK(R) 250 mg DR. FALK PHARMA GMBH

URSOFALK(R) 250 mg DR. FALK PHARMA GMBH

URSOSAN 250 mg PRO. MED. CS PRAHA AS

________________________________________________________________________________
SUBLISTA C1 - G7 CIROZA HEPATICĂ.
______________________________________________________________________________

| 406 |A06AD11| LACTULOSUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A06AD11 LACTULOSUM LICHID ORAL 66.7%

DUPHALAC(R) 66.7% SOLVAY PHARMACEUTICALS BV
A06AD11 LACTULOSUM

LACTULOSE AL SIROP 66.7% ALIUD PHARMA GMBH & CO.KG

A06AD11 LACTULOSUM

LAEVOLAC 670 mg/ml 670 mg/ml FRESENIUS KABI AUSTRIA

GMBH
A06AD11 LACTULOSUM SIROP 66.7%

LACTULOSE AL SIROP 66.7% ALIUD PHARMA GMBH & CO.KG

A06AD11 LACTULOSUM SOL. ORALĂ 670 mg/ml

LAEVOLAC 670 mg/ml 670 mg/ml FRESENIUS KABI AUSTRIA

GMBH
A06AD11 LACTULOSUM SIROP 66.7%

LACTULOSE AL SIROP 66.7% ALIUD PHARMA GMBH & CO.KG

A06AD11 LACTULOSUM SOL. ORALĂ 670 mg/ml

LAEVOLAC 670 mg/ml 670 mg/ml FRESENIUS KABI AUSTRIA

GMBH
A06AD11 LACTULOSUM LICHID ORAL 66.7%

DUPHALAC(R) 66.7% SOLVAY PHARMACEUTICALS BV

A06AD11 LACTULOSUM SIROP 65%

LACTULOSE 65% E.I.P.I.CO. MED S.R.L.

________________________________________________________________________________
______________________________________________________________________________

| 407 |A07AA11| RIFAXIMINUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A07AA11 RIFAXIMINUM COMPR. FILM. 200 mg

NORMIX 200 mg 200 mg ALFA WASSERMANN SPA

________________________________________________________________________________

#M4

______________________________________________________________________________

| 408 | *** Abrogată |

|_______|______________________________________________________________________|
______________________________________________________________________________

| 409 | *** Abrogată |

|_______|______________________________________________________________________|
#B

______________________________________________________________________________

| 410 |C03CA01| FUROSEMIDUM | |

|_______|_______|____________________________________________|_________________|

Electroliţii serici trebuie să fie verificaţi periodic.